Testosterone Enanthate Cancer Risk Signal Review

What the FDA Label Says About Cancer Risk

The current FDA prescribing information for testosterone enanthate carries a formal contraindication for men with known or suspected carcinoma of the prostate or breast. The label also instructs prescribers to assess prostate-specific antigen (PSA) before initiating therapy and at regular intervals thereafter. This language has been in place since the original NDA approval and was reinforced by the 2015 FDA safety communication that added cardiovascular and venous thromboembolic language to all testosterone products.

The Contraindication Is Not a Proven Causal Statement

The contraindication reflects a biologically plausible concern rather than a demonstrated dose-response relationship in randomized trials. Androgen receptor signaling is well-established in prostate epithelium; the Huggins Nobel Prize work from 1941 showed castration caused prostate cancer regression. That observation, however, describes androgen-sensitive disease already present, not de-novo carcinogenesis from exogenous testosterone in men without pre-existing cancer.

The 2018 Endocrine Society Clinical Practice Guideline on male hypogonadism states: "We recommend against starting testosterone therapy in patients who are actively being evaluated for or have been diagnosed with prostate or breast cancer." [1] That phrasing, which targets active evaluation or diagnosis, is more nuanced than a blanket lifetime ban.

Saturation Model and Its Clinical Implications

The saturation model, described by Morgentaler and Traish in 2009, proposes that androgen receptors in prostate tissue become saturated at serum testosterone concentrations near 250 ng/dL. [2] Above that threshold, incremental increases in testosterone produce little additional prostate tissue stimulation. This model, supported by in vitro and small clinical data, is one reason prostate cancer specialists at major academic centers have cautiously administered testosterone to carefully selected hypogonadal men in active surveillance for low-grade prostate cancer (Gleason grade group 1). Randomized trial confirmation at scale is still lacking.

Prostate Cancer: De-Novo Risk Versus Disease Acceleration

The distinction between causing prostate cancer and waking up occult disease matters enormously when counseling patients.

Epidemiological Studies on De-Novo Risk

A 2016 meta-analysis in the Journal of Sexual Medicine (19 studies, N=11,930 men on testosterone therapy) found no statistically significant increase in prostate cancer incidence compared to untreated controls. [3] The pooled relative risk was 1.09 (95% CI 0.83 to 1.42). Heterogeneity across studies was substantial (I² = 64%), which limits firm conclusions, but the point estimate was close to the null.

The RHYME registry, a prospective observational study following 849 men with hypogonadism on testosterone therapy across seven European countries, found a prostate cancer incidence of 1.0 per 100 person-years at 36 months. That rate is not meaningfully higher than the background incidence in age-matched unmedicated men with hypogonadism. [4]

The T-Trials and Prostate Safety

The T-Trials (Testosterone Trials) enrolled 788 men aged 65 and older with low testosterone (average baseline total testosterone: 234 ng/dL) and randomized them to testosterone gel (targeting 500 to 1000 ng/dL) or placebo for 12 months. Published in the New England Journal of Medicine in 2016, the sexual function, vitality, and walking-distance sub-trials all showed statistically significant benefits in the testosterone group. [5]

The T-Trials were not powered to detect prostate cancer as a primary endpoint. Biopsy-detected prostate cancer occurred in 5 men in the testosterone group and 1 in the placebo group, a numerical difference that did not reach statistical significance given the sample size. The investigators explicitly acknowledged this as a safety signal requiring study in larger, longer trials. PSA increased modestly (mean 0.30 ng/mL) in the testosterone group versus placebo at 12 months. [5]

Men with Prior Prostate Cancer on Active Surveillance

Several single-arm series, including a 2011 report by Khera et al. (N=13) and a 2015 series by Pastuszak et al. (N=28), explored testosterone therapy in hypogonadal men on active surveillance for Gleason 6 prostate cancer. Neither series observed pathological progression at 2 to 3 years. [6] These are very small, non-randomized datasets. They do not authorize routine use in this population, but they do inform the shared decision-making conversation for men who are both hypogonadal and on surveillance.

Breast Cancer Risk in Men

Male breast cancer accounts for roughly 1% of all breast cancer diagnoses in the United States, approximately 2,800 new cases annually per CDC estimates. [7] Gynecomastia secondary to testosterone aromatization to estradiol is common with TE; actual malignant transformation from exogenous testosterone is not well-documented.

Aromatization and Estradiol Elevation

Testosterone enanthate aromatizes to estradiol. In a pharmacokinetic study of intramuscular TE 200 mg every two weeks, peak serum estradiol reached approximately 42 pg/mL at day 3 post-injection before declining. [8] Estradiol above 40 pg/mL correlates with gynecomastia in clinical series. While elevated estradiol is the mechanistic concern, no large controlled study has linked TE-associated estradiol elevation to increased male breast cancer incidence.

FDA Label Language

The FDA label for testosterone enanthate lists "known or suspected carcinoma of the male breast" as an absolute contraindication. Any new breast mass, nipple discharge, or skin retraction in a male patient on TE mandates immediate cessation of therapy and breast imaging plus surgical consultation.

Erythrocytosis and Thromboembolic Cancer Confounders

Polycythemia secondary to testosterone therapy is not itself a cancer, but it raises hematocrit and whole-blood viscosity, which can complicate venous thromboembolism risk, a topic occasionally conflated with cancer risk in safety literature.

Mechanism and Prevalence

Testosterone stimulates erythropoietin production in the kidney and may act directly on bone marrow progenitor cells. In a 2013 systematic review (39 trials, N=5,703), injectable testosterone formulations produced clinically meaningful erythrocytosis (hematocrit above 50%) in 5.7% of treated men, compared to 0.9% in placebo groups. [9] TE, given its supraphysiologic peak after intramuscular injection, carries a higher erythrocytosis burden than transdermal formulations at equivalent weekly doses.

Why This Matters for Cancer Monitoring

Men on TE with hematocrit above 54% are at materially higher risk for deep vein thrombosis and pulmonary embolism. Several clotting disorders and some malignancies (renal cell carcinoma being the classic example) independently raise hematocrit through ectopic erythropoietin secretion. A new erythrocytosis on TE therefore warrants ruling out secondary causes, including occult renal or hepatic tumors, before attributing the elevation solely to the drug.

The HealthRX clinical team uses a three-tier erythrocytosis response framework for TE patients:

• Tier 1 (Hct 50 to 52%): Increase monitoring frequency to every 8 weeks; ensure adequate hydration; evaluate for secondary causes if no prior erythrocytosis.
• Tier 2 (Hct 52 to 54%): Reduce TE dose by 25 to 30% or extend injection interval; recheck in 6 weeks; consider switching to a transdermal formulation.
• Tier 3 (Hct >54%): Hold TE immediately; obtain full erythrocytosis workup including serum erythropoietin, renal ultrasound, and pulmonary evaluation; do not reinitiate until Hct falls below 50% and secondary malignant causes are excluded.

Hepatic Tumors: A Class Effect That Does Not Apply to TE

The FDA label for 17-alpha alkylated oral androgens (methyltestosterone, oxymetholone) includes a warning about peliosis hepatis and hepatocellular carcinoma. Testosterone enanthate is an esterified, non-alkylated androgen administered intramuscularly. It bypasses hepatic first-pass metabolism almost entirely and is not associated with hepatotoxicity or hepatic tumor formation at therapeutic doses.

This distinction matters clinically. Patients who read general androgen safety information may conflate oral anabolic steroid hepatotoxicity with injectable TE risk. The hepatic tumor warning in the TE label is retained as a class-wide precaution, not because injectable testosterone has produced hepatic tumors in controlled clinical settings.

PSA Monitoring Protocol and Referral Thresholds

Monitoring PSA is the central safety tool for prostate cancer detection in men on TE. The Endocrine Society 2018 guideline provides the most widely cited thresholds. [1]

Baseline Assessment

Before starting TE, obtain:

• Total and free testosterone (two morning draws, at least one week apart)
• PSA
• Digital rectal exam (DRE) in men aged 40 and older, or in any man with a first-degree relative with prostate cancer
• Complete blood count with hematocrit
• Lipid panel and liver function tests

Men with PSA above 4.0 ng/mL at baseline, or above 3.0 ng/mL with additional risk factors (African American race, first-degree family history), should have urology consultation before TE is prescribed.

On-Treatment Thresholds That Require Urology Referral

Per the Endocrine Society guideline, refer to urology if any of the following occur: [1]

• PSA rises more than 1.4 ng/mL above the confirmed baseline within 12 months
• PSA velocity exceeds 0.4 ng/mL per year over two consecutive years
• PSA crosses the absolute threshold of 4.0 ng/mL (or 3.0 ng/mL in high-risk patients)
• A new abnormality is found on DRE at any point

Timing of PSA Checks Relative to Injection Day

This practical point is under-discussed in guidelines. Testosterone enanthate 200 mg IM produces peak serum testosterone at approximately 72 hours post-injection, then declines over 10 to 14 days. Drawing PSA at the injection peak versus the trough produces slightly different values. The AUA recommends drawing PSA at trough (just before the next scheduled injection) to minimize intra-individual variability and allow valid comparison across visits.

Cardiovascular Risk and Its Interaction with Cancer Screening

The 2010 Basaria et al. Trial in the New England Journal of Medicine (N=209 older men with mobility limitations) was halted early because cardiovascular events occurred in 23 men on testosterone versus 5 on placebo (P<0.001). [10] That trial enrolled a high-risk population with pre-existing cardiovascular disease. The signal prompted the FDA's 2015 label revision requiring a general cardiovascular warning.

Cardiovascular events and cancer are not the same risk, but they interact in clinical practice because:

• Polycythemia from TE elevates both thrombotic and thromboembolic risk.
• Some prostate cancer treatments (ADT with GnRH agonists) cause metabolic syndrome, worsening cardiovascular risk in men who subsequently need testosterone.
• Survivors of testicular cancer (who may be hypogonadal after orchiectomy or chemotherapy) are a special population in whom testosterone therapy decisions intersect directly with cancer history.

Testicular Cancer Survivors and Hypogonadism

Hypogonadism is common after treatment for testicular germ cell tumors. A 2014 study by Haugnes et al. (N=1,431 survivors) found that 12.5% had testosterone levels below 300 ng/dL at long-term follow-up. [11] These men have an established cancer history but do not have active androgen-sensitive disease; prior testicular cancer is not a contraindication to TE. Hormone-producing Leydig cell tumors are the exception; they require individualized oncology and endocrinology co-management before any exogenous androgen is prescribed.

Special Populations: Transgender Men and Off-Label Use

Testosterone enanthate is used off-label in transgender men for gender-affirming hormone therapy, often at doses of 50 to 100 mg IM every one to two weeks. The cancer risk field differs from cisgender male hypogonadism.

Cervical and Uterine Tissue

Transgender men on testosterone retain cervical and uterine tissue unless they have undergone hysterectomy. Testosterone causes endometrial atrophy in most cases, but cervical cancer screening (Pap smear at standard intervals) should continue regardless of testosterone use. The American College of Obstetricians and Gynecologists (ACOG) specifically addresses this in its 2021 guidance on transgender care. [12]

Breast Tissue After Chest Surgery

Transgender men who have had chest masculinization surgery retain small amounts of residual breast tissue. No large-scale registry data have demonstrated an elevated breast cancer incidence in this population on testosterone, but surveillance is appropriate given the biological plausibility of androgen-to-estrogen conversion in residual tissue.

Summarizing the Risk Signal: What the Evidence Actually Shows

Four clinically actionable conclusions emerge from the literature:

1. Testosterone enanthate does not appear to cause prostate cancer in men with normal prostate tissue, based on meta-analytic data through 2024. The pooled relative risk in the largest systematic review sits at approximately 1.09.
2. TE can accelerate occult, androgen-sensitive prostate cancer. Pre-treatment PSA and DRE are non-negotiable before prescribing.
3. Erythrocytosis is the most common TE-related laboratory abnormality with downstream thrombotic implications; hematocrit above 54% requires dose reduction or cessation and a workup that excludes malignant causes of secondary polycythemia.
4. The hepatic tumor risk documented for oral alkylated androgens does not extend to intramuscular TE at therapeutic doses.

The Endocrine Society 2018 guideline summarizes appropriate practice: "We suggest that clinicians adhere to a standard follow-up of 3 to 6 months after initiating testosterone therapy and annually thereafter." [1] At each visit, PSA and hematocrit should be among the values reviewed.